Get the Stockscreener App
2.40
2.13%
0.05
After Hours:
2.41
0.01
+0.42%
Alzamend Neuro Inc stock is traded at $2.40, with a volume of 62,201.
It is up +2.13% in the last 24 hours and down -25.00% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$2.35
Open:
$2.35
24h Volume:
62,201
Relative Volume:
0.04
Market Cap:
$6.95M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.3589
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
+3.45%
1M Performance:
-25.00%
6M Performance:
-75.54%
1Y Performance:
-87.51%
1-Day Range:
$2.33
$2.43
1-Week Range:
$2.14
$2.44
52-Week Range:
$2.06
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.40 | 6.81M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Will Alzamend Neuro Inc. rebound enough to break evenFree Short Term High Yield Stock Tips - Newser
Published on: 2025-08-11 05:11:50 - Newser
Signal strength of Alzamend Neuro Inc. stock in tech scannersSecure Trading Strategy Based on Technical Analysis - Newser
Leading vs lagging indicators on Alzamend Neuro Inc. performanceDay Trading Setup and Momentum Analysis - Newser
Tools to monitor Alzamend Neuro Inc. recovery probabilityPrice Spike Prediction for Active Traders - Newser
How Alzamend Neuro Inc. stock performs during market volatilityPattern Breakout Prediction for Short Term - Newser
Can technical indicators confirm Alzamend Neuro Inc.’s reversalDownside Control Plan With Support Analysis - Newser
What MACD and RSI say about Alzamend Neuro Inc.Stock Entry Point Planner with Volume Spike - Newser
Key resistance and support levels for Alzamend Neuro Inc.Weekly Portfolio Update with ROI Focus - Newser
Visualizing Alzamend Neuro Inc. stock with heatmapsBuy and Hold Position Summary Review - Newser
Why Alzamend Neuro Inc. stock attracts strong analyst attentionAI Short-Term Gain Forecast with Data - Newser
Head-To-Head Review: Alzamend Neuro (NASDAQ:ALZN) & BioAtla (NASDAQ:BCAB) - Defense World
Alzamend Neuro (NASDAQ:ALZN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Published on: 2025-08-09 00:00:57 - Newser
Will Alzamend Neuro Inc. outperform the marketFree Reliable Alerts for Daily Stock Movers - Newser
Regression analysis insights on Alzamend Neuro Inc. performanceWeekly Gain Forecast with Momentum Indicators - Newser
Alzamend Neuro Inc. stock momentum explainedSummary of Consistent Growth Stock Picks - Newser
Alzamend Neuro Inc. Moves Into Overbought Range Analysts CautiousReal Profit Trade Plan Suggestions Shared Widely - beatles.ru
Published on: 2025-08-04 23:59:05 - metal.it
Alzamend Neuro Inc. stock volume spike explainedWeekly Chart Watchlist with Trade Guidance - Newser
What is the dividend policy of Alzamend Neuro Inc. stockAchieve consistent profits with expert advice - Jammu Links News
What are Alzamend Neuro Inc. company’s key revenue driversUnlock exclusive trading tools and resources - Jammu Links News
What are the latest earnings results for Alzamend Neuro Inc.Unlock exclusive investment alerts - Jammu Links News
Is Alzamend Neuro Inc. a growth stock or a value stockLightning-fast capital gains - Jammu Links News
What are the technical indicators suggesting about Alzamend Neuro Inc.Free Investment Community - Jammu Links News
What catalysts could drive Alzamend Neuro Inc. stock higher in 2025Invest smarter with data-backed trading alerts - Jammu Links News
What drives Alzamend Neuro Inc. stock priceAchieve breakthrough financial results - Jammu Links News
What institutional investors are buying Alzamend Neuro Inc. stockTrack high-yield stocks before they peak - Jammu Links News
When is Alzamend Neuro Inc. stock expected to show significant growthNavigate market volatility with smart strategies - Jammu Links News
Why is Alzamend Neuro Inc. stock attracting strong analyst attentionSuperior investment outcomes - Jammu Links News
How does Alzamend Neuro Inc. compare to its industry peersTransform your portfolio with high-yield stocks - Jammu Links News
Alzamend Neuro Increases Common Stock Through Conversion - TipRanks
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):